CM-082
CM-082 is in phase II clinical trials for the treatment of age-related macular degeneration, ovarian cancer, pancreatic cancer, renal carcinoma and other solid tumors.
The compound was originally developed by Tyrogenex. In 2009, the compound was licensed to AnewPharma (卡南吉医药) in China.
General Information
Update Date：2016-02-18
- Drug Name：
- CM-082
- Research Code：
- CM-082
- Trade Name：
- MOA：
- Multi-targeted inhibitor
- Indication：
- Age-related macular degeneration (AMD); Ovarian cancer; Pancreatic cancer; Renal carcinoma; Solid tumours
- Status：
- Phase II (Active)
- Company：
- Tyrogenex (Originator) , AnewPharma
- Sales：
- ATC Code：
Chemical Structure
Update Date：2016-01-20
|
Molecular Weight | |||||||||||||
| Formula | ||||||||||||||
| CAS No. | ||||||||||||||
| Chemical Name | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||